The prepared NPs were able to disrupt the CML-related BCR–ABL gene without affecting the same gene in normal cells thereby improving the survival rate in a CML mouse model [102]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.